首页|Chinese herbal medicine for the treatment of endocrine therapy-related osteoporosis among patients with breast cancer:A systematic review and meta-analysis

Chinese herbal medicine for the treatment of endocrine therapy-related osteoporosis among patients with breast cancer:A systematic review and meta-analysis

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
Objective:To assess the efficacy and safety of combining traditional Chinese medicine(TCM),specifically Chinese herbal medicine(CHM),with Western medicine(WM),compared to WM alone to treat breast cancer endocrine therapy-related osteoporosis(BCET-OP)by meta-analysis.Methods:Thirty-eight randomized controlled trials involving 2170 participants were analyzed.Eight databases were searched for articles published between inception and December 2023.Quality assess-ment was performed using the Risk of Bias 2 tool.Results:Significant increases were observed in the TCM-WM group in lumbar vertebrae bone mineral density(BMD)(P＜.001,mean difference(MD)=0.07,95％confidence interval(CI):0.06 to 0.08),lumbar vertebrae T-score(P=.0005,MD=0.21,95％CI:0.09 to 0.33)and collum femoris BMD(P=.01,MD=0.10,95％CI:0.02 to 0.19).No significant difference was observed between the groups in the collum femoris T-score and estradiol levels.Bone gla-protein levels were significantly increased in the TCM-WM group(P=.0002,MD=0.52,95％CI:0.25 to 0.79).Beta-CrossLaps decreased significantly in the TCM-WM group(P=.0008,MD=-0.10,95％CI:-0.16 to-0.04).No significant difference was observed between the TCM-WM and WM groups in alkaline phosphatase,in procollagen type Ⅰ N-terminal pro-peptide,and in the Kupperman index.The visual analog score(VAS)was decreased in the TCM-WM group compared to the WM group(P＜.001,MD=-1.40,95％CI:-1.94 to-0.87).No significant dif-ference in adverse events was observed between the two groups.Conclusion:Combining CHM with WM in patients with BCET-OP significantly improved BMD,T-score,and certain bone turnover markers and reduced the VAS score,indicating potential benefits for bone health and related pain.Adverse event analysis revealed no differences between the groups,supporting the feasibility of the combination therapy.However,further research,particularly in diverse populations,is required.

Breast cancerEndocrine therapyOsteoporosisTraditional Chinese medicineMeta-analysis

Xiaomin Quan、Hongyang Chen、Wenyi Wang、Yu Gao、Xingyue Zhi、Xun Li、Guanhu Yang、Donggui Wan、Chao An

展开 >

Department of Oncology,Dongfang Hospital Beijing University of Chinese Medicine,100078,Beijing,China

Department of Oncology,China-Japan Friendship Hospital,100029,Beijing,China

Department of Nephrology,Beijing University of Chinese Medicine Third Affiliated Hospital,100029,Beijing,China

Center for Evidence-Based Chinese Medicine,Beijing University of Chinese Medicine,100029,Beijing,China

Department of Specialty Medicine,OHIO University,Athens,OH 45701,USA

展开 >

Program of Introducing Talents of Discipline to Universities(111 Project)-TCM Prevention and Treatment of Major Chronic Dise

Tumor-B21028

2024

10.1016/j.jtcms.2024.03.004

中医科学杂志(英文)
北京中医药大学,清华大学出版社有限公司

中医科学杂志(英文)

ISSN：2095-7548
年,卷(期)：2024.11(2)
  • 67